arrow
D

Deepti Radia

Department of Clinical Haematology
H指数:33
被引数:5,336

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Patient-Reported Outcomes and Provider Perceptions of Systemic Mastocytosis: Results From the PRISM Study

患者报告结局和医疗提供者对系统性肥大细胞增多症的认知:PRISM研究的结果

2025-06-270
PREAI
Harmonization of Diagnostic Criteria in Mastocytosis for Use in Clinical Practice: WHO vs ICC vs AIM/ECNM
2024-12-012
OAAI
QRISK3: A New Marker for Thrombotic Events in Essential Thrombocythemia and Polycythemia Vera at Diagnosis and during Follow up

QRISK3:一种用于诊断及随访期间真性红细胞增多症和原发性血小板增多症血栓事件的新的标志物

BLOOD
IF23.1
2024-11-050
PRE
Ultra-Sensitive KIT testing Uncovers Previously Undetected KIT mutations in Patients with Indolent Systemic Mastocytosis: Results from the Pioneer Trial

超敏KIT检测发现惰性系统性肥大细胞增多症患者中先前未检出的KIT突变:先锋试验结果

BLOOD
IF23.1
2024-11-051
PRE
Allogeneic haematopoietic cell transplantation for advanced systemic mastocytosis: Best practice recommendations on behalf of the EBMT Practice Harmonisation and Guidelines Committee
LEUKEMIA
IF13.4
2024-03-123
PRE
The Normal Range of Baseline Tryptase Should Be 1 to 15 ng/mL and Covers Healthy Individuals With HαT

基线类胰蛋白酶的正常范围应为1至15 ng/mL,并涵盖患有h α t的健康个体

2023-10-0122
OAAI
European Competence Network on Mastocytosis (ECNM): 20-Year Jubilee, Updates, and Future Perspectives
2023-06-014
OAAI
Third-dose SARS-CoV-2 mRNA vaccine increases Omicron variant neutralization in patients with chronic myeloid disorders
2023-05-100
OAAI
CNL and aCML should be considered as a single entity based on molecular profiles and outcomes
2023-04-2614
OAAI
Mast Cell Diseases in Practice and Research: Issues and Perspectives Raised by Patients and Their Recommendations to the Scientific Community and Beyond
2022-08-0111
OAAI